AJMC, October 2019 –In Orphanet Journal of Rare Diseases, researchers analyzed the impact of hereditary ATTR amyloidosis morbidity and mortality on government costs in the Netherlands. The authors found that hereditary ATTR amyloidosis patients in the Netherlands paid fewer taxes but received more from the government in the form of pensions, disability payments and healthcare. The assessment highlighted that delaying disease progression can be fiscally beneficial to governments when considering future taxes and lower disability payments.